

New Tests on the Horizon For Detecting Latent TB

BY BRUCE K. DIXON
Chicago Bureau

KEYSTONE, COLO. — New tests that detect latent tuberculosis infection by quantifying interferon- γ released from sensitized lymphocytes in whole blood may be a big step toward the elimination of TB, Dr. Charles Daley said at a meeting on allergy/clinical immunology, asthma, and pulmonary medicine.

This class of tests, called in vitro T-cell-based interferon- γ release assays (IGRAs), is the first replacement for the flawed tuberculin skin test, which has been in use in one form or another for a century.

"We absolutely can and must replace the tuberculin skin test, and the reason we can is because of these specific mycobacterium tuberculosis antigens, ESAT-6 and CFP-10," Dr. Daley said at the meeting, sponsored by the National Jewish Medical and Research Center.

The first replacement for the tuberculin skin test in a century, Quantiferon-TB (Cellestis), was approved by the Food and Drug Administration in 2001.

A version called Quantiferon-TB Gold In-Tube, which should be available this summer, will allow the drawing of blood directly into tubes containing the antigens, said Dr. Daley, who is head of mycobacterial and respiratory infections at National Jewish, Denver.

Another impending test is T-Spot.TB (Oxford Immunotec Ltd.), which detects or spots individual T cells, and can be used for the diagnosis of latent disease simply by detecting the presence of an effector T-cell response.

A major advantage of these new tests is that they avoid false-positive results caused by previous inoculation with the BCG vaccine, which is widely used outside the United States and is a critical factor in the screening of foreign-born individuals.

"Over time, this cross-reactivity has led to a distrust of the skin test in vaccinated people, many of whom can't remember when or even if they received BCG," Dr. Daley explained.

Dr. Daley, who consults for both companies, said that IGRAs are more sensitive and specific than the tuberculin skin test. Both of the IGRAs correlate with exposure better than the tuberculin skin test, and may be more cost effective as well, he explained.

In addition, IGRAs require only one patient visit, assess responses to multiple antigens simultaneously, do not boost anamnestic immune responses, provide results within a day, and greatly reduce interreader variability.

A prospective study of 393 consecutively enrolled patients with latent tuberculosis infection or suspected TB looked at agreement between the tuberculin skin test and both interferon- γ release assays, and found that indeterminate results were more common with Quantiferon-TB than with T-Spot.TB, particularly in young children and those who were immunocompromised (Lancet 2006;367:1328-34).

More needs to be learned about using IGRAs for serial testing. To that end, Dr. Daley and others are launching a four-center U.S. study of 3,000 health care workers who will be tested every 6 months with skin tests and both IGRAs.

Meanwhile, Dr. Daley and his colleagues at National Jewish are using Quantiferon-TB Gold and will begin using T-Spot.TB this summer. ■




A new class of tuberculosis tests, in vitro T-cell-based interferon- γ release assays, may become available soon, Dr. Charles Daley said.

MARCIA WARD

NEW INDICATION—for the treatment of moderate to severe primary RLS

Restless Legs Syndrome (RLS)... simplified.



Mirapex[®]
pramipexole dihydrochloride tablets
A new choice for RLS

- Efficacy:** MIRAPEX demonstrated statistically significant superiority for IRLS and CGI-I vs placebo^{1*}
- Safety:** MIRAPEX was studied in nearly 1000 RLS patients for up to 9 months—and has a decade of experience in treating Parkinson's disease¹
- Convenience:** MIRAPEX offers convenient dosing and titration

IMPORTANT SAFETY INFORMATION ABOUT MIRAPEX: Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle. Hallucinations and postural (orthostatic) hypotension may occur. The most commonly reported adverse events in RLS clinical trials for MIRAPEX vs placebo were nausea (16% vs 5%), headache (16% vs 15%), fatigue (9% vs 7%), and somnolence (6% vs 3%).

Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease and RLS.

Please see accompanying Brief Summary of Prescribing Information.

^{*}Results of a 12-week, placebo-controlled, randomized, double-blind, fixed-dose-treatment trial to assess the efficacy and safety of MIRAPEX vs placebo in the treatment of moderate to severe primary RLS (MIRAPEX n=254; placebo n=85). Measurement parameters included the International Restless Legs Syndrome Rating Scale (IRLS) and the Clinical Global Impressions-Improvement (CGI-I) scale. IRLS is an internationally validated scale that is the standard instrument for evaluation of severity of RLS. Total score ranges from 0 to 40, with 0 being absence of RLS symptoms and 40 the most severe symptoms. CGI-I is widely accepted for measuring improvement in RLS symptoms.

Reference: 1. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.



Copyright © 2007, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
Printed in U.S.A. (01/07) MRLS11741ROBB

www.mirapex.com